(TSX Venture: ARCH) (OTCQB: ACHFF) announced in a press release today that patient recruitment and dosing have begun in ...

And now, they are looking at a major breakthrough in treating common injuries and diseases where organ inflammation affects millions of patients globally annually with an LSALT peptide.

Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...